MedTrace Logo

Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme

NCT00574964 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-10-27

No results posted yet for this study

Summary

The purpose of this research study is to determine if combining all three treatments of Gliadel wafers, Temozolomide and Radiation therapy at the same time is safe and more effective than one treatment at a time. The study will measure the survival of subjects treated with this combination of drugs.

Conditions

  • Primary Glioblastoma Multiforme

Interventions

OTHER

Gliadel Wafer, Temodar and Radiotherapy

Given concurrently starting 10-30 days after surgery.

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • University of Iowa

    lead OTHER

Principal Investigators

  • Timothy Ryken, MD · University of Iowa

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-11-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00574964 on ClinicalTrials.gov